2 results
Approved WMORecruiting
To assess the time to progression after TACE-DEB and after SBRT in a comparable population of patients diagnosed with HCC.
Approved WMOCompleted
Primary Objective:To demonstrate that CHF 1535 twice daily is superior to Formoterol twice daily in terms of COPD exacerbations rate during 48 weeks of treatment and in terms of pulmonary function (change in pre-dose morning FEV1 from baseline to 12…